Juan Gilabert Estellés

Simple radiologic assessment of visceral obesity and prediction of surgical morbidity in endometrial cancer patients undergoing laparoscopic aortic lymphadenectomy: A reliability and accuracy study

AbstractAimTo evaluate the reliability of sagittal abdominal diameter (SAD)—a surrogate of visceral obesity—in magnetic resonance imaging, and its accuracy to predict the surgical morbidity of aortic lymphadenectomy.MethodsWe conducted a multicenter reliability (phase 1) and accuracy (phase 2) cohort study in three Spanish referral hospitals. We retrospectively analyzed data from the STELLA‐2 randomized controlled trial that included high‐risk endometrial cancer patients undergoing minimally invasive surgical staging. Patients were classified into subgroups: conventional versus robotic‐assisted laparoscopy, and transperitoneal versus extraperitoneal technique. In the first phase, we measured the agreement of three SAD measurements (at the umbilicus, renal vein, and inferior mesenteric artery) and selected the most reliable one. In phase 2, we evaluated the diagnostic accuracy of SAD to predict surgical morbidity. Surgical morbidity was the main outcome measure, it was defined by a core outcome set including variables related to blood loss, operative time, surgical complications, and para‐aortic lymphadenectomy difficulty.ResultsIn phase 1, all measurements showed good inter‐rater and intra‐rater agreement. Umbilical SAD (u‐SAD) was the most reliable one. In phase 2, we included 136 patients. u‐SAD had a good diagnostic accuracy to predict surgical morbidity in patients undergoing transperitoneal laparoscopic lymphadenectomy (0.73 in ROC curve). It performed better than body mass index and other anthropometric measurements. We calculated a cut‐off point of 246 mm (sensitivity: 0.56, specificity: 0.80).Conclusionsu‐SAD is a simple, reliable, and potentially useful measurement to predict surgical morbidity in endometrial cancer patients undergoing minimally invasive surgical staging, especially when facing transperitoneal aortic lymphadenectomy.

Exploring the feasibility of anti-PD-1/PD-L1 immunotherapy in endometriosis-associated ovarian cancer